|Jointly provided by ProCE, LLC and Paradigm Medical Communications, LLC.|
Differentiating influenza from other viruses, and treating high-risk patients in a timely manner to avoid overburdening the healthcare system, has never been more relevant. Join us for a timely, expert-led CE activity that will marry the current data and guideline recommendations on influenza testing, diagnosis, and antiviral treatment with engaging whiteboard animation case studies, so you are prepared to apply the latest updates in influenza to clinical practice now.
This activity has been designed to address the educational needs of community, health-system, and hospital pharmacists. It may also benefit other clinicians involved in the care of patients with, or at risk for, influenza virus infection.
Upon proper completion of this activity, participants should be better able to:
- Identify appropriate candidates for antiviral therapy based on risk for influenza-related complications, in accordance with current guideline recommendations
- Assess the need for influenza treatment based on patient signs, symptoms, and accurate interpretation of appropriate diagnostic tests when necessary
- Recommend individualized antiviral treatment plans for patients with, or at risk for, influenza in accordance with the latest evidence
Jason E. Bowling, MD
Department of Medicine
Division of Infectious Diseases
UT Health San Antonio
San Antonio, TX
Katherine Lusardi, PharmD
Clinical Pharmacy Specialist
UAMS Medical Center
Little Rock, AR
Release Date: November 30, 2020
Expiration Date: November 30, 2021
This CE activity is jointly provided by ProCE, LLC and Paradigm Medical Communications, LLC. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-243-H01-P has been assigned to this home study knowledge-based CE activity (initial release date 8-27-2020). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the posttest with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given. ACPE requires that CE credit be claimed within 60 days of completion of the post-test and evaluation. There is no fee required for participation in this activity.
In accordance with ACPE requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Jason E. Bowling, MD - No financial relationships to disclose.
Katherine Lusardi, PharmD - Consulting Fees: Accelerate Diagnostics, Inc
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
ProCE, LLC staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
ProCE, LLC and Paradigm Medical Communications, LLC have implemented a system to resolve conflicts of interest for each CPE activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CPE content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACPE guidelines.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CPE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, ProCE, LLC or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.
As accredited providers, ProCE, LLC and Paradigm Medical Communications, LLC's activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by ProCE, LLC or Paradigm Medical Communications, LLC.
© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Hardware /Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.